Advances in the Management of Metastatic Castration-Resistant Prostate Cancer: Expert Guidance and Resources for the Interdisciplinary Team

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with metastatic castration-resistant prostate cancer.

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Target Audience

This educational program is intended for oncology physicians, nurses, nurse practitioners, pharmacists, physician associates, and other healthcare professionals who care for patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal evidence-based treatment and supportive care options for patients with newly diagnosed mCRPC, mCRPC with HRR gene alterations, and recurrent mCRPC
  • Counsel patients and caregivers on unique toxicities associated with targeted therapies used to treat mCRPC and provide guidance on AE management
  • Develop a proactive management plan to support adherence in patients with prostate cancer receiving oral therapies, including identifying potential adherence barriers and implementing strategies to overcome them
  • Identify all patients with prostate cancer who may be eligible to ensure equitable enrollment in ongoing clinical studies investigating novel regimens, considering potential racial, age, and socioeconomic disparities
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca and Novartis Pharmaceuticals Corp. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
12/21/2023
Course expires: 
12/21/2024
Cost:
$0.00

Xin Gao, MD
Assistant Professor of Medicine 
Harvard Medical School
Medical Oncologist
Medicine-Hematology/Oncology
Massachusetts General Hospital
Boston, Massachusetts

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Presenting Faculty

Xin Gao, MD
Bayer HealthCare: Consultant/Advisor/Speaker
Flare Therapeutics Inc.: Consultant/Advisor/Speaker
Guardant Health: Consultant/Advisor/Speaker
Myovant Sciences GmbH: Consultant/Advisor/Speaker
PathAI, Inc.: Consultant/Advisor/Speaker
PureTech Health: Consultant/Advisor/Speaker
Silverback Therapeutics, Inc.: Consultant/Advisor/Speaker

Program Co-Chairs

Alan Bryce, MD
Astellas Pharma US, Inc.: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
Bayer HealthCare: Consultant/Advisor/Speaker
Janssen Pharmaceutica Products, LP: Consultant/Advisor/Speaker; Grant/Research Support
Merck & Co., Inc.: Consultant/Advisor/Speaker
Myovant Sciences GmbH: Consultant/Advisor/Speaker
Pfizer Inc.: Consultant/Advisor/Speaker

Rana R. McKay, MD
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
AVEO Pharmaceuticals, Inc.: Consultant/Advisor/Speaker
Bayer HealthCare: Consultant/Advisor/Speaker
Bristol-Myers Squibb Company: Consultant/Advisor/Speaker
Calithera Biosciences, Inc.: Consultant/Advisor/Speaker
Caris Life Sciences: Consultant/Advisor/Speaker
Dendreon Corporation: Consultant/Advisor/Speaker
Eli Lilly and Company: Consultant/Advisor/Speaker
Eisai Inc.: Consultant/Advisor/Speaker
Exelixis Inc.: Consultant/Advisor/Speaker
Johnson & Johnson: Consultant/Advisor/Speaker
Merck & Co., Inc.: Consultant/Advisor/Speaker
Myovant Sciences GmbH: Consultant/Advisor/Speaker
Novartis Pharmaceuticals Corporation: Consultant/Advisor/Speaker
Pfizer Inc.: Consultant/Advisor/Speaker
sanofi-aventis U.S.: Consultant/Advisor/Speaker
SeaGen: Consultant/Advisor/Speaker
Sorrento Therapeutics, Inc.: Consultant/Advisor/Speaker
Telix Pharmaceuticals Limited: Consultant/Advisor/Speaker
Tempus: Consultant/Advisor/Speaker

NCCN and CCO Staff Disclosures

None of the planners/managers for this educational activity has relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this application-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-23-134-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until December 21, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing